Regulatory filings and commercialization, potential safety and regulatory issues that could deploy the spend or terminate clinical studies. Regulatory approvals for sales, uncertain timelines, costs, and results of clinical trials and development of new products; our ability to plan, and manage cost reduction or operational efficiency initiatives; the scope and validity of intellectual property rights applicable to products being developed. Our ability to maintain our remedial actions over previously reported material weaknesses and internal controls over financial reporting and our estimates for the relative fair values on the recent agreements with Phillips. May change and change our final reporting financial results.These and other risks are described in greater detail under the heading Risk Factors contained in our periodic SEC filings, including our annual reports on Form 10-K filed with the SEC on March 16, 2011. Given these uncertainties, you should not place undue reliance on the forward-looking statements in this call. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future even if new information becomes available.
Hansen Medical CEO Discusses Q1 2011 Results - Earnings Call Transcript
Check Out Our Best Services for Investors
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.